Gene Expression Helps Predict Benefit From Adjuvant Chemo for Breast Cancer
Although nearly 60% of all patients with early-stage breast cancer are given adjuvant chemotherapy, only 2%–15% of them receive clinical benefit, according to research published in the 2016 American Society of Clinical Oncology Educational Book.
October 18, 2016
Outpatient Oncology Drug Series: Oxaliplatin Hates the Cold
Oxaliplatin is a cytotoxic (toxic to normal cells) chemotherapy drug that is classified as an alkylating agent as well as a platinum analogue. It is indicated for a number of different cancers including colorectal, esophageal, gastric, hepatobiliary, Non-Hodgkin lymphoma, ovarian, pancreatic, and testicular cancer.
January 16, 2015